Michele Till, MD; Keith B. MacDonell, MD
Recent data indicate that early therapy with zidovudine is beneficial in slowing disease progression in persons infected with the human immunodeficiency virus type 1 (HIV-1) when CD4 cell counts are less than 500 cells/ mm3 (1). Many persons infected with HIV-1 will be taking zidovudine over long periods, and clinicians may be faced with related complications. One such complication is the development of a drug-induced myopathy. Although muscle pathologies including inflammatory myopathy (2-5), type II atrophy (6), and nemaline rod myopathy (2, 7, 8) had been described in association with HIV-1 infection before use of zidovudine, there are now several
Learn more about subscription options.
Register Now for a free account.
Till M, MacDonell KB. Myopathy with Human Immunodeficiency Virus Type 1 (HIV-1) Infection: HIV-1 or Zidovudine?. Ann Intern Med. 1990;113:492–494. doi: 10.7326/0003-4819-113-7-492
Download citation file:
Published: Ann Intern Med. 1990;113(7):492-494.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only